Business Context and Reporting Period
Zura Bio Limited, a Cayman Islands-based emerging growth company, filed this Form 8-K on February 24, 2026. The filing primarily reports the entry into a material definitive agreement for a public equity offering and provides preliminary financial condition updates as of December 31, 2025.
Key Financial Metrics
- Offering Proceeds: The Company agreed to sell 18,200,000 Class A ordinary shares at $6.25 per share and 1,800,000 pre-funded warrants at $6.249 per warrant. The underwriters exercised their full option to purchase an additional 3,000,000 shares.
- Net Proceeds: Expected net proceeds are approximately $134.6 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Cash Position: As of December 31, 2025, the Company held approximately $109.4 million in cash and cash equivalents. This figure is preliminary and unaudited.
- Share Count: Following the offering, the total outstanding ordinary shares are expected to be 94,875,460 (assuming no exercise of pre-funded warrants).
Material Changes
The primary material change is the significant capital raise via the Offering. The Company's cash position is projected to increase substantially upon the closing of the transaction, which is expected on February 26, 2026. Additionally, the share count will increase from 65,018,058 (as of September 30, 2025) plus 8,657,402 shares issued to Athanor Capital in December 2025, to the post-offering total of 94,875,460 shares.
Outlook, Risks, and Contingencies
- Closing Conditions: The Offering is subject to customary closing conditions and is expected to close on February 26, 2026.
- Warrant Terms: Pre-funded warrants are exercisable immediately but are subject to a 9.99% beneficial ownership limitation, which can be increased to 19.99% with 61 days' prior notice.
- Forward-Looking Statements: The filing contains forward-looking statements regarding net proceeds and closing dates, which are subject to market uncertainties and may differ materially from actual results.
- Financial Data Reliability: The cash balance of $109.4 million is a preliminary estimate subject to adjustment upon completion of financial closing procedures and audits.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after all expenses.
- Confirm the final audited cash and cash equivalents balance for the period ended December 31, 2025.
- Monitor the exercise activity of the 1,800,000 pre-funded warrants issued in the offering.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.